HealthDay - WEDNESDAY, Feb. 1 (HealthDay News) -- U.S. Food and Drug
Administration approval for the Novartis drug Gleevec has been expanded to
include adults who have had surgical removal of CD117-positive
gastrointestinal stromal tumors (GIST), the agency said in a news
release.